Loop Diuretics Administration and Acute Heart Failure
Information source: University of Siena
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Acute Heart Failure
Intervention: furosemide infusion (Drug)
Phase: Phase 4
Status: Recruiting
Sponsored by: University of Siena Overall contact: Alberto Palazzuoli, MD, Phone: +39577585363, Email: palazzuoli2@unisi.it
Summary
Intravenous loop diuretics is the therapy most commonly used to treat pulmonary congestion
and systemic fluid overload. In theory, continuous infusion should allow for a more
consistent diuresis, avoiding the sodium reabsorption in the distal tubule as well as the
neurohormonal activation. This should lead to renal function improvement and BNP decrease.
Clinical Details
Official title: Continuous Versus Intermittent Loop Diuretics Infusion Dosing in Acute Heart Failure: Effects on Renal Function, Outcome and BNP Levels
Study design: Observational Model: Cohort, Time Perspective: Retrospective
Primary outcome: evaluation of renal function and BNP levels during loop diuretic infusion
Secondary outcome: length of hospitalization and evaluation of cardiac events in the two groups
Eligibility
Minimum age: 40 Years.
Maximum age: 90 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patients took part in the random sample selection if they met the diagnostic criteria
for acute decompensated HF.
- They also displayed impaired ejection fraction (LVEF <45%) with cardiac
dilatation and pulmonary hypertension
Exclusion Criteria:
- Patients were excluded if they had received more than 2 IV doses of furosemide or any
continuous infusion of furosemide 1 month before randomization
- If they had end-stage renal disease or the need for renal replacement therapy,
isolated diastolic dysfunction
- Recent myocardial infarction
Locations and Contacts
Alberto Palazzuoli, MD, Phone: +39577585363, Email: palazzuoli2@unisi.it
Department of Internal Medicine, Cardiology Section Center, Siena, 53100, Italy; Recruiting Alberto Palazzuoli, MD, Phone: +39577585363, Email: palazzuoli2@unisi.it Alberto Palazzuoli, MD, Principal Investigator
Additional Information
Starting date: April 2010
Last updated: September 23, 2011
|